오믹스 기반 임상시험 시장 : 단계별, 시험 설계별, 적응증별 - 세계 예측(2025-2030년)

The Omics-Based Clinical Trials Market was valued at USD 30.10 billion in 2023, expected to reach USD 32.51 billion in 2024, and is projected to grow at a CAGR of 8.39%, to USD 52.92 billion by 2030.

Omics-based clinical trials represent a crucial component of precision medicine, integrating genomics, proteomics, metabolomics, and other omics technologies to tailor therapies towards individual patients' unique biological profiles. The necessity for such trials is driven by the increasing demand for personalized medical treatments, which can improve efficacy and minimize side effects. They are applied across various stages of drug development, from biomarker discovery to patient stratification in treatment responses. End-use scope includes pharmaceuticals, biotechnology companies, and academic research institutions, all leveraging omics data to enhance clinical outcomes. Market growth is influenced by technological advancements in high-throughput sequencing, data analytics, and the expanding role of AI in analyzing complex datasets. Increasing collaborations between research institutions and pharmaceutical companies to accelerate drug discovery also propel market expansion. However, one of the significant challenges is the high cost associated with omics data collection and analysis, coupled with data privacy concerns and the complexity of integrating multi-omics datasets. Limited standardization in data handling also affects trial consistency and reproducibility. Within this rapidly evolving market, opportunities lie in the development of cost-effective data analytics platforms and personalized therapeutic solutions, especially in oncology where omics have shown considerable promise. Investment in robust bioinformatics tools and efforts towards regulatory harmonization across regions can bolster market growth. Successful navigation involves adopting an agile approach to technological integration while ensuring patient data security and ethical standards. Companies can innovate by focusing on improving the accuracy and speed of omics-based diagnostics and treatments. Insightful opportunities await in niche applications like rare diseases and genetic disorders, where omics can make a significant difference. Overall, the market for omics-based clinical trials is complex yet promising, with a substantial capacity for innovation and specialization.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Omics-Based Clinical Trials Market

The Omics-Based Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising investment in the pharmaceutical research and development sector
  • Increasing prevalence and burden of various chronic diseases globally
  • Growing focus on personalized medicine and oncology trials
• Market Restraints
  • High cost of omics-based clinical trials products
• Market Opportunities
  • Upsurging consumer awareness and adoption of multi-omics solutions
  • Proliferation in the number of amalgamation activities across the globe
• Market Challenges
  • Issues relating to effective data analysis

Porter's Five Forces: A Strategic Tool for Navigating the Omics-Based Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Omics-Based Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Omics-Based Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Omics-Based Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Omics-Based Clinical Trials Market

A detailed market share analysis in the Omics-Based Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Omics-Based Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Omics-Based Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Omics-Based Clinical Trials Market

A strategic analysis of the Omics-Based Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Omics-Based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Complete Omics, Inc., Covance Inc., Danaher Corporation, Eli Lilly and Company, ICON Plc, Laboratory Corporation of America Holdings, Merck & Co. Inc., Mission Bio, Inc., NeoGenomics Laboratories, Inc., Novo Nordisk A/S, Parexel International Corporation, Pfizer, Inc., Rebus Biosystems, Inc., SGS SA, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Omics-Based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
• Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies.
• Based on Indication, market is studied across Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising investment in the pharmaceutical research and development sector
    • 5.1.1.2. Increasing prevalence and burden of various chronic diseases globally
    • 5.1.1.3. Growing focus on personalized medicine and oncology trials
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of omics-based clinical trials products
  • 5.1.3. Opportunities
    • 5.1.3.1. Upsurging consumer awareness and adoption of multi-omics solutions
    • 5.1.3.2. Proliferation in the number of amalgamation activities across the globe
  • 5.1.4. Challenges
    • 5.1.4.1. Issues relating to effective data analysis
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Omics-Based Clinical Trials Market, by Phase

• 6.1. Introduction
• 6.2. Phase I
• 6.3. Phase II
• 6.4. Phase III
• 6.5. Phase IV

7. Omics-Based Clinical Trials Market, by Study Design

• 7.1. Introduction
• 7.2. Expanded Access Studies
• 7.3. Interventional Studies
• 7.4. Observational Studies

8. Omics-Based Clinical Trials Market, by Indication

• 8.1. Introduction
• 8.2. Cardiology
• 8.3. CNS Diseases
• 8.4. Genetic Diseases
• 8.5. Immunology
• 8.6. Oncology
• 8.7. Respiratory Diseases
• 8.8. Skin Diseases

9. Americas Omics-Based Clinical Trials Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Omics-Based Clinical Trials Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Omics-Based Clinical Trials Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Complete Omics, Inc.
• 2. Covance Inc.
• 3. Danaher Corporation
• 4. Eli Lilly and Company
• 5. ICON Plc
• 6. Laboratory Corporation of America Holdings
• 7. Merck & Co. Inc.
• 8. Mission Bio, Inc.
• 9. NeoGenomics Laboratories, Inc.
• 10. Novo Nordisk A/S
• 11. Parexel International Corporation
• 12. Pfizer, Inc.
• 13. Rebus Biosystems, Inc.
• 14. SGS SA
• 15. Thermo Fisher Scientific, Inc.